Singapore Lab Fast-Tracks Ebola Defense

syringe needle drawing liquid from a vaccine vial — Photo: Numstocker / Shutterstock

A Singapore-based lab is racing to build the World Health Organization’s “most promising” Ebola vaccine as a rare Bundibugyo outbreak explodes in central Africa.

Story Snapshot

Global health agencies say there is still no licensed vaccine or treatment for Bundibugyo Ebola virus, despite a fast-growing outbreak.
The World Health Organization picked a single-dose rVSV Bundibugyo vaccine as the most promising candidate and urged rapid clinical trials.
Singapore’s Hilleman Laboratories will now manufacture doses of this vaccine candidate for human testing, backed by international funding.
The same rVSV technology underpins Merck’s approved Ervebo Ebola shot, which showed strong protection in past trials.

Deadly Bundibugyo Ebola Outbreak Drives Urgent Vaccine Push

The current Ebola disease outbreak caused by Bundibugyo virus in the Democratic Republic of the Congo and Uganda has been declared a public health emergency of international concern by the World Health Organization. Health officials report thousands of suspected and confirmed cases and hundreds of deaths, with control still far from where it needs to be. Unlike previous Ebola crises, this one is driven by the rarer Bundibugyo strain, which has no approved vaccine or specific treatment, leaving local families exposed and health workers with only basic tools.

World Health Organization officials explain that outbreak control now relies on classic public health steps like rapid case detection, isolation, contact tracing, infection prevention, and safe burials. These measures can slow spread but cannot fully replace a strong vaccine in regions where health systems are weak and borders are porous. Past Bundibugyo outbreaks showed that delays in spotting cases allowed the virus to circulate for months, underscoring how fragile surveillance is and why medical countermeasures are urgently needed to protect communities and keep the crisis from spilling wider.

WHO Backs Single‑Dose rVSV Bundibugyo Vaccine as Top Candidate

In late May, experts convened by the World Health Organization reviewed all known Bundibugyo vaccine options and named a single‑dose recombinant vesicular stomatitis virus Bundibugyo shot, called rVSV Bundibugyo, as the most promising candidate to prevent disease. This vaccine, developed by the International AIDS Vaccine Initiative, uses the same rVSV technology as Merck’s Ervebo shot for the Zaire Ebola strain, which delivered strong protection in large trials. World Health Organization advisors said the rVSV Bundibugyo vaccine should be advanced into clinical trials as quickly as possible to help close the major gap in defenses.

That expert group also flagged another Bundibugyo vaccine candidate, ChAdOx1 Bundibugyo, from Oxford University and the Serum Institute of India, which could reach testing readiness sooner but was not judged to be the lead option. The single‑dose rVSV Bundibugyo candidate is expected to need seven to nine months of further work before it can be assessed in people for real‑world protection. Preclinical studies in non‑human primates have already shown survival benefits, adding weight to the World Health Organization’s view that this design stands out in the current pipeline and deserves priority.

Singapore’s Hilleman Laboratories Steps In to Produce Trial Doses

To turn this scientific plan into actual vials for doctors, the Coalition for Epidemic Preparedness Innovations has partnered with Hilleman Laboratories, a Singapore‑based joint venture between United States pharmaceutical company Merck (also known as MSD) and the British charity Wellcome. Up to 8.5 million United States dollars in funding will help Hilleman Laboratories finalize the manufacturing process and produce clinical supplies of the rVSV Bundibugyo vaccine candidate at its vaccine facility in Singapore. The company will start from material created by the International AIDS Vaccine Initiative and may later support other rVSV‑based vaccines against different deadly viruses.

🇨🇩 BREAKING: DRC Ebola outbreak hits 3,075 cases, 1,354 deaths.

⚡ Fastest-growing outbreak in history
⚡ Rare Bundibugyo strain — no cure
⚡ WHO declares global health emergency

👇 Should the world respond faster?#DRC #Ebola #GlobalHealth #WHO #BreakingNews pic.twitter.com/oW41S1fvQW

— Septentria News (@SeptentriaNews) July 27, 2026

Merck’s experience with the Ervebo Ebola vaccine gives this Singapore project access to proven know‑how on the rVSV platform, including how to design, scale, and stabilize live recombinant viral vaccines. Scientific reviews have long described rVSV‑based Ebola vaccines as among the most promising filovirus tools under development, with single‑shot regimens protecting animals against several Ebola species in demanding tests. For African countries now facing Bundibugyo Ebola without any licensed countermeasure, advancing this candidate into human trials offers a realistic path toward a targeted shot rather than relying on partial cross‑protection from Zaire‑focused vaccines that were not built for this strain.

What This Means for Global Health and American Interests

The Centers for Disease Control and Prevention says no Bundibugyo Ebola cases from this outbreak have been confirmed in the United States and the current risk to the American public remains low. Still, the agency has activated a public health emergency response to support international efforts and track any change in risk. The Africa Centres for Disease Control and Prevention describe the situation as a public health emergency of continental security, emphasizing that instability, weak health systems, and hunger are all made worse by unchecked disease.

For American conservatives who value strong borders and limited but effective government, this story highlights how dangerous viruses can spread in fragile regions and then threaten wider stability if left unmanaged. Bundibugyo Ebola lacks a licensed vaccine or treatment, and that gap forces the world to depend on fast‑tracked research and foreign production capacity. Singapore’s rVSV Bundibugyo project shows how targeted science, clear priorities from the World Health Organization, and focused funding can build real defenses without endless bureaucracy—an approach that protects American interests by stopping deadly threats before they reach our shores.